Overview


According to FutureWise analysis the market for biobanking is expected to reach US$ 6.95 billion by 2031 at a CAGR of 11.62%.

Clinical trials have improved in recent years due to the use of biospecimens for clinical research. With the increasing demand for clinical trials across the world, especially for diseases like cancer, shall boost the biobanking market growth substantially. Human biospecimens are increasingly used for cohort studies. According to the study conducted by the National Institutes of Health, the number of recorded clinical studies increased from over 180,000 in 2014 to over 262,000 in 2017. Such an increased emphasis on developing novel therapies shall boost the market growth. Furthermore, there has been a rapid evolution in the market with advancements in genetic technology as they can raise demand for biospecimen of the highest quality to propel cancer research. For example, Indivumed, in 2017, partnered with Northwell Health to create a research biobank for cancer. Moreover, the current developments in automation and information technologies has helped in improving the operational efficiency of biobanks with features like fully automatic and pre-programmed refrigerators and freezers that support temperature monitoring. Additionally, the UK biobanks in March 2017, partnered with Regeneron Genetics Center and GSK and under this partnership the 5000,000 samples stored by UK biobanks were all sequenced by Regeneron. Such collaboration shall bolster the market growth. Emergence of notable upgrades in biobanking operations for ensuring an optimized sample storage and maintenance, thereby driving the proliferation of the market.

  • Thermo Fisher Scientific Inc.
  • Tecan Group Ltd.
  • Qiagen N.V.
  • Hamilton Company
  • Brooks Automation
  • TTP Labtech Ltd.
  • VWR Corporation
  • Promega Corporation
  • Worthington Industries [(Taylor Wharton]
  • Chart Industries
  • Becton Dickinson and Company
  • Merck KGaA
  • Micronic
  • LVL Technologies GmbHCo. KG
  • Panasonic Healthcare Holdings Co. Ltd.
  • Greiner Bio One
  • Biokryo GmbH
  • Biobank AS
  • Biorep Technologies Inc.
  • Cell & Co Bioservices
  • RUCDR infinite biologics
  • Modul-Bio
  • CSols Ltd.
  • Ziath LabVantage Solutions Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Products and Services

  • Biobanking Equipment
    • Temperature Control Systems
      • Freezers and Refrigerators
      • Cryogenic Storage Systems
      • Thawing Equipment
    • Incubators and Centrifuges
    • Alarms and Monitoring Systems
    • Accessories and Other Equipment
  • Biobanking Consumables
  • Laboratory Information Management Systems
  • Biobanking and Repository
  • Lab Processing
  • Qualification/Validation
  • Cold Chain Logistics
  • Other Services

By Biospecimen Type

  • Human Tissues
  • Organs
  • Stem Cells
    • Adult Stem Cells
    • Embryonic Stem Cells
    • IPS Cells
    • Other Stem Cells
  • Other Biospecimen

By Biobank Type

  • Physical/Real
    • Tissue
    • Population Based
    • Genetic
    • Disease Based
  • Virtual

By Application

  • Therapeutics
  • Drug Discovery and Clinical Research
  • Clinical Diagnostics
  • Others

By Region

The market is fragmented into by products and services, by biospecimen type, by biobank type, by application and region. The products and services segment is categorized into biobanking equipment, biobanking consumables, laboratory information management systems, biobanking and repository, lab processing, qualification/validation, cold chain logistics and other services. Equipment like freezers, barcode readers, cell separators, alarm monitoring systems and thawing equipment are available for the process of biobanking like sample analysis, collection, transport and storage. Laboratory information management systems are utilized in different biobank workflows like sample collection, patient consent, sample storage, accession and distribution. But these workflows can only be used for newer samples and in case of older samples, the usage of these workflows is reduced to data storage. National Cancer Institute developed a Biobank Economic Modeling Tool in 2017 was used for undertaking a survey which concluded that the consumables held the largest biobanking market share owing to its integrated usage with equipment that are based on novel technologies like automated sample processing shall boost the market growth. Rise in the clinical trial outsourcing has bolstered the proliferation of the market. The application segment is categorized into therapeutics, drug discovery and clinical research, clinical diagnostics and others. The therapeutics segment is anticipated to lead the market owing to rapid advancements in biologic production has boosted the augmentation of the market. The biospecimen type segment is bifurcated into human tissues, organs, stem cells and other biospecimens. Serum or plasma, solid tissues, peripheral blood, bone marrow and whole blood are some specimens that are generally stored in the biorepositories. The human tissue segment is predicted to dominate the market owing to advancements in cell acquisition technology and a wide range of stem cell applications for regenerative medicines shall boost the growth of the market.

The North America region is expected to lead the market, and this is primarily due to various strategic partnerships and collaborations between ley market players for developing advanced technologies for biobanks in the region. The European region is predicted to grow at a substantial rate during the forecast period owing to advancements in infrastructure for storage, retrieval and processing biospecimens. The BBMRI and EuroBioBank are two of the largest biobanking networks currently operating in the region for bolstering research and medical activities.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key market trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global biobanking market By Products And Services, By Biospecimen Type, By Biobank Type, By Application and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Biobanking Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Biobanking Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Biobanking Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Biobanking Market, By Products and Services Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Biobanking Equipment
         1.1. Temperature Control Systems
          1.1.1. Freezers and Refrigerators
          1.1.2. Cryogenic Storage Systems
          1.1.3. Thawing Equipment
         1.2. Incubators and Centrifuges
         1.3. Alarms and Monitoring Systems
         1.4. Accessories and Other Equipment
        2. Biobanking Consumables
        3. Laboratory Information Management Systems
        4. Biobanking and Repository
        5. Lab Processing
        6. Qualification/Validation
        7. Cold Chain Logistics
        8. Other Services

  • 8.   Biobanking Market, By Biospecimen Type Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Human Tissues
        2. Organs
        3. Stem Cells
         3.1. Adult Stem Cells
         3.2. Embryonic Stem Cells
         3.3. IPS Cells
         3.4. Other Stem Cells
        4. Other Biospecimen

  • 9.   Biobanking Market, By Biobank Type Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Physical/Real
         1.1. Tissue
         1.2. Population Based
         1.3. Genetic
         1.4. Disease Based
        2. Virtual

  • 10.   Biobanking Market, By Application Historical Analysis and Forecast 2023-2031 (USD million)
    •   1. Therapeutics
        2. Drug Discovery and Clinical Research
        3. Clinical Diagnostics
        4. Others

  • 11.   North America Biobanking Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Biobanking Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Biobanking Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Biobanking Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Thermo Fisher Scientific Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Tecan Group Ltd.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Qiagen N.V.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Hamilton Company
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Brooks Automation
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. TTP Labtech Ltd.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. VWR Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Promega Corporation
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Worthington Industries
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Chart Industries
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Becton Dickinson and Company
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Merck KGaA
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Micronic
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. LVL Technologies GmbHCo. KG
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Panasonic Healthcare Holdings Co. Ltd.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Greiner Bio One
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Biokryo GmbH
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Biobank AS
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Biorep Technologies Inc.
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Cell & Co Bioservices
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. RUCDR infinite biologics
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
        22. Modul-Bio
         22.1. Company Overview
         22.2. Product Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
        23. CSols Ltd.
         23.1. Company Overview
         23.2. Product Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview
        24. Ziath LabVantage Solutions Inc.
         24.1. Company Overview
         24.2. Product Portfolio
         24.3. SWOT Analysis
         24.4. Financial Overview
         24.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients